Jaguar health, inc. (JAGX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Jun'14Mar'14
Cash flows from operating activities
Net loss

-38,171

-38,539

-45,233

-43,817

-34,753

-32,146

-39,699

-28,801

-22,949

-21,968

0

0

0

-14,733

-16,338

-16,291

0

0

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

1,732

1,737

1,634

1,532

1,426

1,319

1,247

1,213

898

584

0

0

0

0

0

-

-

-

-

-

-

Interest paid on the conversion of debt to equity

-

-

-

-

-

-21

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued in exchange for services rendered

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs and debt discount

-

-

-

-

-

-

-

-

-

-

-

0

0

483

2,005

2,720

0

0

0

-

-

Change in fair value of warrants and conversion option liability

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Accretion of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Warrants issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

501

0

0

0

-

-

Loss on extinguishment of debt

-

-4,940

0

0

0

-

-

-

-

-477

0

0

0

-

-

-

-

-

-

-

-

Amortization of operating lease right-of-use-assets

326

191

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Expense on modification of warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Materials cost in connection with license activity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

0

0

0

0

0

Stock-based compensation

3,321

2,988

2,590

2,160

2,178

2,023

1,600

1,107

858

814

0

0

0

593

1,043

992

0

0

0

-

-

Amortization of debt issuance costs and debt discount

4,993

5,157

4,767

4,258

971

1,196

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants, conversion option and derivative liability

-1,056

-1,009

-830

-26

-228

-6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Changes in assets and liabilities
Accounts receivable

168

696

564

1,513

551

528

269

274

66

166

0

0

0

-10

4

55

0

0

0

-

-

Other receivable

12

7

-176

22

-0

4

159

-127

-285

1

0

0

0

-

-

-

-

-

-

-

-

Inventory

-256

-1,213

-227

-451

631

1,269

718

660

147

-128

0

0

0

-30

-44

31

0

0

0

-

-

Prepaid expenses and other current assets

207

246

-58

-921

92

111

523

871

-71

143

0

0

0

-

-

-

-

-

-

-

-

Prepaid license fee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

701

503

299

0

0

0

0

0

Deferred offering costs

-

-

-

-

-

-

-

-

-

-72

0

0

0

-

-

-

-

-

-

-

-

Other non-current assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred collaboration revenue

-

-

-

-

-

-177

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

Operating lease liabilities

-158

-132

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Due from former parent

-

-

-

-

-

-

-

-

-

-164

0

0

0

5

-23

-19

0

0

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Deferred product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-110

-109

228

0

0

0

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

License fee payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,450

-1,600

-1,200

0

0

0

-

-

Accounts payable

-1,021

-62

-1,698

1,389

3,402

-1,940

-1,407

-1,075

-935

4,188

0

0

0

15

-1,202

-240

0

0

0

0

0

Accrued expenses

-920

-1,059

385

3,853

4,146

3,260

2,642

430

-1,375

141

0

0

0

205

-930

-546

0

0

0

0

0

Total cash used in operating activities

-21,287

-20,456

-22,219

-16,483

-16,574

-22,730

-23,158

-23,377

-19,157

-9,824

0

0

0

-

-

-

-

-

-

-

-

Total cash used in operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17,504

-14,315

0

0

0

0

0

Cash flows from investing activities
Purchase of equipment

0

-

-

-

-

6

0

0

0

-

-

-

-

0

0

-

-

-

-

-

-

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

Total cash used in investing activities

0

-

-

-

-

-6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Total cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Cash flows from financing activities
Proceeds from issuance of notes payable, net of issuance costs and debt discount

4,600

5,050

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loan advance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Repayment of notes payable

-

-

-

-

-

-

-

-

-

2,422

0

0

0

0

0

-

-

-

-

-

-

Proceeds from issuance of redeemable convertible preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from issuance of convertible debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,250

0

0

0

-

-

Proceeds from issuance of long term debt

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of notes payable

5,100

5,150

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of underwriting discounts, commissions and other associated offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

417

0

0

0

0

0

Proceeds from issuance of common stock through a stock purchase agreement with a private investor

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock in follow-on secondary public offering, net of commissions, discounts

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

Total cash provided by financing activities

20,325

21,771

23,562

15,685

11,338

24,545

23,170

24,591

27,303

10,679

0

0

0

-

-

-

-

-

-

-

-

Net increase in cash and restricted cash

-968

1,315

1,343

-804

-5,236

1,808

-5

-349

6,582

-702

0

0

0

-

-

-

-

-

-

-

-

Supplemental schedule of cash flow information
Cash paid for interest

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total Cash Provided by Financing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26,882

24,170

0

0

0

0

0

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,504

6,467

6,852

0

0

0

0

0

Supplemental schedule of non-cash financing and investing activities
Interest paid on long-term debt

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

346

0

0

0

0

0

Warrants issued in connection with convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

Abatement of license fee payable to Napo

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

250

0

0

0

-

0

Common stock issued in exchange for CVP Exchange Note 1 principal and related interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Accretion to redemption value of Series A redeemable convertible preferred stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fixed assets in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Series B convertible preferred stock
Series B convertible preferred stock inducement expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series 2 warrants
Proceeds from issuance of common stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series 1 warrants
Proceeds from issuance of common stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2019 Bridge Note Warrants
Proceeds from issuance of common stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Private Investment in Public Entities
Proceeds from the issuance of convertible preferred stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Private Investment in Public Entities March 2018
Proceeds from the issuance of convertible preferred stock, March 2018

-

-

-

-

-

9,199

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Issuance costs associated with the issuance of convertible preferred stock, March 2018

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Private Investment in Public Entities December 2017
Proceeds from the issuance of common stock

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Notes payable
Common stock issued as redemption of notes payable and related interest

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of warrants

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Jaguar Notes Payable
Common stock issued as redemption of notes payable and related interest

-

-

-

-

-

1,153

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Napo convertible debt
Common stock issued as redemption of notes payable and related interest

-

-

-

-

-

1,638

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

March 2019 letter of credit warrant
Issuance of warrants

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series A convertible preferred stock
Accretion to redemption value of Series A redeemable convertible preferred stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B-2 convertible preferred stock
Conversion of Series B-2 convertible preferred stock into common stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-